Source: Unsplash 

The munKNEE Pure-Play Marijuana-Based & Psychedelic Compounds-Based Drug Stocks Index consists of 8 constituents in each of the munKNEE Pure-Play Marijuana-Based Drug Stocks Index and the munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index. Which index out-performed in September? This article has the answer. Here are the details:

100 clinical-stage psychedelic drug stocks now trade on North American stock exchanges. 60 of the stocks research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances (read 10 Psychedelic Substances And The 36 Companies Researching Them) and 40 research the treatment of illnesses based on the use of THC marijuana (read Marijuana Drug Stocks: All You Need To Know).

The criteria for inclusion in the munKNEE Pure-Play Marijuana-Based & Psychedelic Compounds-Based Drug Stocks Index is that its constituents have market capitalizations in excess of $50M but less than $500M and only 16 of the 100 psychedelic drug stocks meet that criteria. The remaining 84 stocks in the Index have market caps below $50M or are above $500M. The latter include ATAI, Compass Pathways, Mind Medicine, and GH Resources and they are not included in the index given their very large market caps and high share prices which would have dominated the index's performance. 

The Pure-Play Marijuana-Based Drug Stocks Category

The 8 marijuana-based clinical-stage stocks consist of Allied (ALID), Corbus (CRBP), Enveric (ENVB), MGC Pharma (MGCLF), Revive (RVVTF), Tetra Bio (TBPMF), Zelira (ZLDAF), and Zynerba (ZYNE). In total, they

• were UP +22.2% in September 
• are now UP +5.5% YTD,
• range in price from C$0.03/share to $4.23/share for an average of $1.36/share  (Currency amounts are in U.S. dollars. Go here to convert to another currency),
• and have an average market capitalization of approximately $104M.

Those that changed in price by +/-5% so far in September are presented below in descending order including YTD percentage movements. 

1. Allied Corp.: UP+181.6% in September and is now UP +286.7% YTD
2. Enveric: UP +14.4% but is still DOWN -51.4% YTD
3. Revive: UP +5.9% but is still DOWN -26.5% YTD
4. Corbus: DOWN -17.7% and is now DOWN -18.4% YTD
5. Tetra Bio: DOWN -20.8% but is still UP +26.7% YTD

The Pure-Play Psychedelic Compounds-Based Drug Stocks Category

The 8 psychedelic compound-based clinical-stage stocks consist of Awakn (AWKNF), Cybin (CYBN), Field Trip (FTRP), Mydecine (MYCOF), Numinus (LKYSF), Red Light (TRUFF), Seelos (SEEL), and Small Pharma (DMTTF) and, on average, they

• are DOWN -12.3% in September, 
• but are still UP +31.7% YTD,
• range in price from $0.16/share to $4.59/share for an average of $1.53/share (Currency amounts are in U.S. dollars. Go here to convert to another currency),
• and have an average market capitalization of $200M.

Those that changed in price by +/-5% in September are presented below in descending order including YTD percentage movements. 

1. Awakn Life: UP +18.7% in September and is now DOWN -24.3% since beginning to trade on June 23rd
2. Seelos: UP +11.6% and is now UP +52.5% YTD
3. Numinus: DOWN -8.8% and is now DOWN -26.2% YTD
4. Field Trip: DOWN -20.2% but is still UP +41.2% YTD
5. Red Light: DOWN -23.8% and is now DOWN -36.0% YTD
6.  Cybin: DOWN -27.5%but is still UP +46.0% YTD
7. Mydecine: DOWN -31.6% and is now DOWN -25.7% YTD

In Summary

In combined total, the munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index was UP +1.1% in September and is now UP +16.8% YTD

In answer to the opening question as to which Index out-performed in September, the answer is:

• the Marijuana-Based Drug Stocks Index went UP +22.2% in September and is now UP +5.5% YTD while
• the Psychedelic Compounds-Based Index went DOWN -12.3% in September but is still UP +31.7% YTD.